Primecap Management Co. CA Purchases 76,400 Shares of Edwards Lifesciences Corporation $EW

Primecap Management Co. CA grew its stake in Edwards Lifesciences Corporation (NYSE:EW) by 2.2% in the 3rd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 3,523,291 shares of the medical research company’s stock after buying an additional 76,400 shares during the quarter. Primecap Management Co. CA owned 0.61% of Edwards Lifesciences worth $274,006,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. True Wealth Design LLC raised its stake in Edwards Lifesciences by 251.5% in the third quarter. True Wealth Design LLC now owns 362 shares of the medical research company’s stock valued at $28,000 after buying an additional 259 shares during the period. NewSquare Capital LLC lifted its position in shares of Edwards Lifesciences by 57.8% during the 2nd quarter. NewSquare Capital LLC now owns 366 shares of the medical research company’s stock valued at $29,000 after acquiring an additional 134 shares during the period. Rakuten Securities Inc. raised its position in shares of Edwards Lifesciences by 413.7% in the 2nd quarter. Rakuten Securities Inc. now owns 375 shares of the medical research company’s stock valued at $29,000 after buying an additional 302 shares in the last quarter. Hantz Financial Services Inc. raised its holdings in shares of Edwards Lifesciences by 76.6% during the 3rd quarter. Hantz Financial Services Inc. now owns 378 shares of the medical research company’s stock worth $29,000 after buying an additional 164 shares in the last quarter. Finally, Steigerwald Gordon & Koch Inc. acquired a new stake in Edwards Lifesciences in the third quarter valued at about $30,000. 79.46% of the stock is owned by institutional investors.

Edwards Lifesciences Trading Up 1.2%

Edwards Lifesciences stock opened at $83.37 on Thursday. The stock has a market cap of $48.38 billion, a P/E ratio of 45.56, a PEG ratio of 2.15 and a beta of 0.94. The company has a debt-to-equity ratio of 0.06, a quick ratio of 3.29 and a current ratio of 4.00. The firm’s fifty day moving average price is $82.70 and its 200-day moving average price is $81.13. Edwards Lifesciences Corporation has a fifty-two week low of $65.94 and a fifty-two week high of $87.89.

Edwards Lifesciences (NYSE:EW) last posted its quarterly earnings data on Tuesday, February 10th. The medical research company reported $0.58 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.62 by ($0.04). The company had revenue of $1.57 billion for the quarter, compared to the consensus estimate of $1.54 billion. Edwards Lifesciences had a return on equity of 14.50% and a net margin of 17.69%.The business’s revenue was up 13.3% on a year-over-year basis. During the same period in the prior year, the firm posted $0.59 earnings per share. Edwards Lifesciences has set its Q1 2026 guidance at 0.700-0.760 EPS. Equities research analysts forecast that Edwards Lifesciences Corporation will post 2.45 earnings per share for the current fiscal year.

Insider Transactions at Edwards Lifesciences

In related news, CFO Scott B. Ullem sold 7,700 shares of the stock in a transaction dated Tuesday, December 9th. The shares were sold at an average price of $84.47, for a total value of $650,419.00. Following the completion of the transaction, the chief financial officer directly owned 39,898 shares of the company’s stock, valued at $3,370,184.06. This represents a 16.18% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, VP Daniel J. Lippis sold 1,019 shares of the firm’s stock in a transaction that occurred on Friday, January 9th. The shares were sold at an average price of $85.70, for a total value of $87,328.30. Following the completion of the transaction, the vice president owned 22,002 shares of the company’s stock, valued at approximately $1,885,571.40. The trade was a 4.43% decrease in their position. The SEC filing for this sale provides additional information. In the last ninety days, insiders sold 43,804 shares of company stock valued at $3,699,082. Company insiders own 1.29% of the company’s stock.

Analyst Ratings Changes

Several analysts recently weighed in on the stock. Robert W. Baird set a $90.00 price objective on shares of Edwards Lifesciences in a research note on Monday, January 12th. Wells Fargo & Company raised their target price on Edwards Lifesciences from $96.00 to $100.00 and gave the stock an “overweight” rating in a research note on Wednesday, February 11th. Truist Financial set a $89.00 price objective on shares of Edwards Lifesciences and gave the stock a “hold” rating in a report on Wednesday, February 11th. TD Cowen raised shares of Edwards Lifesciences from a “hold” rating to a “buy” rating in a research report on Friday, January 9th. Finally, UBS Group reissued a “neutral” rating and issued a $94.00 price objective on shares of Edwards Lifesciences in a research note on Wednesday, February 4th. Three equities research analysts have rated the stock with a Strong Buy rating, fifteen have issued a Buy rating and nine have issued a Hold rating to the stock. Based on data from MarketBeat, Edwards Lifesciences presently has a consensus rating of “Moderate Buy” and a consensus target price of $96.14.

Edwards Lifesciences Profile

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.